The $65.6 Billion Secret Wall Street Doesn’t Want You to Know About Cardinal Health

Cardinal Health (NYSE: CAH | CAH Price Prediction) delivered a decisive second-quarter beat on February 5, 2026, with non-GAAP EPS of $2.63, surpassing the $2.38 consensus estimate by 10.5%. Revenue climbed 19% year-over-year to $65.63 billion, topping the $64.79 billion estimate. Shares surged 8% over the past week to $228.25, significantly outpacing the S&P 500’s 23% decline over the same period.

Broad-Based Segment Strength

The healthcare distributor achieved double-digit profit growth across all five operating segments. The Pharmaceutical and Specialty Solutions segment, Cardinal’s largest, generated $60.7 billion in revenue, up 19% on brand and specialty pharmaceutical demand. Global Medical Products and Distribution revenue rose 3% to $3.26 billion, but segment profit more than doubled to $37 million, up 106% year-over-year.

Non-GAAP operating earnings jumped 38% to $877 million, while operating cash flow swung to $686 million from a $396 million outflow in the prior-year quarter. CEO Jason Hollar said, “Our strong second-quarter performance reflects at least double-digit segment profit growth across all five of our operating segments. Our ongoing momentum and the team’s consistent execution against our strategic priorities gives us confidence to raise our fiscal 2026 outlook.”

Raised Guidance Reflects Momentum

Management lifted full-year fiscal 2026 non-GAAP EPS guidance to $10.15 to $10.35, representing 23% to 26% growth. This marks a meaningful increase from the prior $9.65 to $9.85 range established after Q1. The company raised its Pharma segment profit growth outlook to 20% to 22% from 16% to 19%, and increased GMPD segment profit guidance to approximately $150 million from $140 million.

Capital Allocation and Strategic Moves

Cardinal completed its $750 million annual baseline share repurchase and reached its targeted 3.2x leverage ratio. The company paid a $0.52 quarterly dividend and continues expanding through acquisitions, including Solaris Health, a leading urology MSO with over 750 providers. With a forward P/E of 22x and analyst price targets averaging $234, the stock trades at a modest premium to growth expectations despite its 81% one-year gain.